| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy
|
Grossfeld, Gary D
|
|
2001
|
58 |
2S1 |
p. 56-64
9 p.
|
artikel
|
| 2 |
Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development
|
Lieberman, Ronald
|
|
2001
|
58 |
2S1 |
p. 83-90
8 p.
|
artikel
|
| 3 |
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer 4 4 Arimidex, Casodex, and Nolvadex are trademarks of the AstraZeneca group of companies.
|
Kolvenbag, Geert J.C.M
|
|
2001
|
58 |
2S1 |
p. 16-22
7 p.
|
artikel
|
| 4 |
CME: Sponsorship/Conference participants
|
|
|
2001
|
58 |
2S1 |
p. v-vi
nvt p.
|
artikel
|
| 5 |
CME: Title/Test/Answer
|
|
|
2001
|
58 |
2S1 |
p. 141-146
6 p.
|
artikel
|
| 6 |
Discussion following Dr. Anthony D’Amico’s presentation
|
|
|
2001
|
58 |
2S1 |
p. 82-
1 p.
|
artikel
|
| 7 |
Discussion following Dr. Deborah P. Lubeck’s presentation
|
|
|
2001
|
58 |
2S1 |
p. 99-100
2 p.
|
artikel
|
| 8 |
Discussion following DR. Don W. W. Newling’s presentation
|
|
|
2001
|
58 |
2S1 |
p. 55-
1 p.
|
artikel
|
| 9 |
Discussion following Dr. François Meyer’s presentation
|
|
|
2001
|
58 |
2S1 |
p. 77-
1 p.
|
artikel
|
| 10 |
Discussion following Dr. Gary D. Grossfeild's presentation
|
|
|
2001
|
58 |
2S1 |
p. 64-
1 p.
|
artikel
|
| 11 |
Discussion following dr. Geert J.C.M. Kolvenbag’S presentation
|
|
|
2001
|
58 |
2S1 |
p. 23-
1 p.
|
artikel
|
| 12 |
Discussion following Dr. Glenn J. Bubley’s presentation
|
|
|
2001
|
58 |
2S1 |
p. 9-
1 p.
|
artikel
|
| 13 |
Discussion following Dr. Hans J. Stricker’s presentations
|
|
|
2001
|
58 |
2S1 |
p. 27-
1 p.
|
artikel
|
| 14 |
Discussion following Dr. Harry W. Daniell’s presentation
|
|
|
2001
|
58 |
2S1 |
p. 106-107
2 p.
|
artikel
|
| 15 |
Discussion following Dr. Martin E. Gleave’s presentation
|
|
|
2001
|
58 |
2S1 |
p. 48-49
2 p.
|
artikel
|
| 16 |
Discussion following Dr. S. Bruce Malkowicz’s presentation
|
|
|
2001
|
58 |
2S1 |
p. 113-
1 p.
|
artikel
|
| 17 |
Discussion following Dr. Sophie Chen’s (pages 28–35) and Dr. John F. Pirani’s presentations
|
|
|
2001
|
58 |
2S1 |
p. 38-
1 p.
|
artikel
|
| 18 |
Discussion following Dr. William R. Fair’s presentation of Dr. Paul F. Schellhammer’s paper
|
|
|
2001
|
58 |
2S1 |
p. 15-
1 p.
|
artikel
|
| 19 |
Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer
|
Meyer, François
|
|
2001
|
58 |
2S1 |
p. 71-77
7 p.
|
artikel
|
| 20 |
Early versus late androgen deprivation therapy in metastatic disease
|
Newling, Don W.W
|
|
2001
|
58 |
2S1 |
p. 50-55
6 p.
|
artikel
|
| 21 |
Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia
|
Bostwick, David G
|
|
2001
|
58 |
2S1 |
p. 91-93
3 p.
|
artikel
|
| 22 |
Growth factors and their receptors: new targets for prostate cancer therapy 1 1 At the time of submission, all authors were employees of the supporter of this supplement.
|
Barton, Jeremy
|
|
2001
|
58 |
2S1 |
p. 114-122
9 p.
|
artikel
|
| 23 |
In vitro mechanism of PC spes
|
Chenn, Sophie
|
|
2001
|
58 |
2S1 |
p. 28-35
8 p.
|
artikel
|
| 24 |
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy
|
Uchida, Atsushi
|
|
2001
|
58 |
2S1 |
p. 132-139
8 p.
|
artikel
|
| 25 |
Is the flare phenomenon clinically significant?
|
Bubley, Glenn J
|
|
2001
|
58 |
2S1 |
p. 5-9
5 p.
|
artikel
|
| 26 |
Luteinizing hormone–releasing hormone antagonists in prostate cancer
|
Stricker, Hans J
|
|
2001
|
58 |
2S1 |
p. 24-27
4 p.
|
artikel
|
| 27 |
Luteinizing hormone–releasing hormone monotherapy: a viable option for treatment of prostate cancer?
|
Schellhammer, Paul F
|
|
2001
|
58 |
2S1 |
p. 10-15
6 p.
|
artikel
|
| 28 |
Osteoporosis due to androgen deprivation therapy in men with prostate cancer
|
Daniell, Harry W
|
|
2001
|
58 |
2S1 |
p. 101-106
6 p.
|
artikel
|
| 29 |
Overview consensus statement
|
Carroll, Peter R
|
|
2001
|
58 |
2S1 |
p. 1-4
4 p.
|
artikel
|
| 30 |
Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
|
D’Amico, Anthony
|
|
2001
|
58 |
2S1 |
p. 78-82
5 p.
|
artikel
|
| 31 |
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer
|
Peehl, Donna M
|
|
2001
|
58 |
2S1 |
p. 123-126
4 p.
|
artikel
|
| 32 |
The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer
|
Lubeck, Deborah P
|
|
2001
|
58 |
2S1 |
p. 94-99
6 p.
|
artikel
|
| 33 |
The effects of phytotherapeutic agents on prostate cancer: an overview of recent clinical trials of PC spes
|
Pirani, John F.
|
|
2001
|
58 |
2S1 |
p. 36-38
3 p.
|
artikel
|
| 34 |
The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States
|
Sylvester, John
|
|
2001
|
58 |
2S1 |
p. 65-70
6 p.
|
artikel
|
| 35 |
The role of cyclooxygenase-2 in prostate cancer
|
Kirschenbaum, Alexander
|
|
2001
|
58 |
2S1 |
p. 127-131
5 p.
|
artikel
|
| 36 |
The role of diethylstilbestrol in the treatment of prostate cancer
|
Malkowicz, S.Bruce
|
|
2001
|
58 |
2S1 |
p. 108-113
6 p.
|
artikel
|
| 37 |
Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer
|
Gleave, Martin E
|
|
2001
|
58 |
2S1 |
p. 39-48
10 p.
|
artikel
|
Tijdschrift beschrijving